微小管の不安定化がiPS細胞由来巨核球からの血小板産生を促進~最終分化段階における新たなメカニズムを解明~

ad

2025-07-02 京都大学iPS細胞研究所

京都大学iPS細胞研究所(CiRA)などの研究グループは、iPS細胞から作製した巨核球から血小板を効率よく産生する新たな方法を発見した。血小板産生を促進する薬剤スクリーニングにより、微小管の脱重合を誘導するビンクリスチンとビンブラスチンがプロプレートレット形成を促進し、血小板の産生量が最大で約3倍増加した。さらに、適度な乱流刺激との併用により、微小管構造が減少し、血小板産生効率がさらに高まることが確認された。得られた血小板はマウスモデルで止血能を保持しており、機能的にも有効であることが示された。従来は微小管構造の維持が巨核球の成熟と血小板産生に不可欠とされていたが、本研究は最終分化段階では微小管の不安定化が産生を促進することを理論的に示し、従来の常識を覆す重要な成果である。iPS細胞由来血小板製剤の製造工程への応用が期待される。

微小管の不安定化がiPS細胞由来巨核球からの血小板産生を促進~最終分化段階における新たなメカニズムを解明~
図1 微小管脱重合を促進する化合物がプロプレートレットを増加させる

<関連情報>

hiPSC由来巨核球終末分化株における微小管不安定化と血小板収率の関連性 Association of microtubule destabilization with platelet yields in terminally differentiating hiPSC-derived megakaryocyte lines

Emiri Nakamura,Yasuo Harada,Trevor Bingham,Christian Skorik,Anjali Jha,John Atwater,Natsumi Higashi,Kosuke Fujio,Mariko Ishiguro,Haruki Okamoto,Leonard I. Zon,George Q. Daley,Andrew L. Frelinger,Koji Eto,Thorsten M. Schlaeger
PLOS One  Published: June 25, 2025
DOI:https://doi.org/10.1371/journal.pone.0326165

Abstract

Millions of platelet units are needed each year to manage thrombocytopenia and other conditions linked to excessive bleeding. These life-saving treatments still depend entirely on donated platelets, despite the numerous shortcomings associated with them, such as limited shelf life, supply shortages, unpredictable functionality, potential for infection, as well as immune-incompatibility issues. These challenges could be overcome with universal donor platelets generated from human induced pluripotent stem cell (hiPSC)-derived megakaryocytes (MKs). We recently developed expandable hiPSC-derived megakaryocytic cell lines (imMKCLs) as a potentially unlimited source for platelet production. imMKCL-derived platelets are functional and have already been tested in patients. In this study, we demonstrate through single-cell time-course imaging that imMKCL maturation is heterogeneous and asynchronous, with only a few imMKCLs generating platelets at any given time under static culture conditions. Using a chemical screen, we identify microtubule (MT) destabilizing agents, including vincristine (VCR), as promising hits, with a larger proportion of VCR-exposed imMKCLs developing proplatelet extensions and more platelets being produced per imMKCL. VCR use reduces the MT content of imMKCLs and results in the production of platelets with a diminished peripheral MT ring structure. Nevertheless, these platelets are functional, as evidenced by their normal response to agonists, their ability to attach to and spread on fibrinogen-coated surfaces, and their capacity to restore hemostasis in vivo. Interestingly, we also observed a negative correlation between the MT content of imMKCLs and platelet yields when we compared imMKCLs differentiated under static conditions (MThigh, low yield) to our turbulence-optimized VerMES™ bioreactor (MTlow, high yield). Taken together, our findings highlight the importance of MT dynamics in megakaryocyte biology, provide a possible explanation for the still poorly understood link between vinca alkaloid in vivo use and thrombocytosis, and bring us closer to realizing the clinical potential of affordable, off-the-shelf hiPSC-derived platelets.

生物化学工学
ad
ad
Follow
ad
タイトルとURLをコピーしました